PLUS THERAPEUTICS, INC.
Last · —$3.8380.00 (0.00%)stale · yahoo · 41h ago
Market cap$26.64M—
P/E · TTM0.2fwd — · eps —
Beta—vs S&P 500
Div yield—annual · TTM
52w range
——
Volume—session
| Revenue | $5.8M |
|---|---|
| Operating income | $-14.7M |
| Net income | $-13.0M |
| Free cash flow | $-10.7M |
| Operating margin | -252.3% |
| Net margin | -222.8% |
| Return on equity | -237.6% |
| Period | 2024 |
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2025-03-31
- Operating Cf Burn
- Net Margin Sharply Negative
- Cash Conversion Weak
- Cash Runway Low
- Current Ratio Low
- Rd Intensity High
Red flags
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -222.8%
- Cash Conversion Weak — Cash conversion (CFO/Rev) -181.2%
- Cash Runway Low — Cash runway ~0.0 years
- Current Ratio Low — Current ratio 0.34
- Rd Intensity High — R&D/Revenue 181.7%
Press & signals
- GlobeNewswire
Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings
- GlobeNewswire
Cerenome Secures In-Network Agreement with Blue Cross Blue Shield of Michigan, Expanding CNSide® Contracted Coverage to Approximately 158 Million Covered Lives
- GlobeNewswire
Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division
The rest of this company's wire — with summaries and source links — is part of Pro.
See plans